Abiopharma

🔍 Skelly Jonathan (Executive)

Company: James Hardie Industries plc (JHX)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Sold 15,000 shares of Ordinary shares at $30.45 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 309,906.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 50,000 shares of Ordinary shares at $11.23 per share (Direct)
  Date: 2026-08-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 359,906.00 | transaction_form_type: 4
• Sold 50,000 shares of Ordinary shares at $30.46 per share (Direct)
  Date: 2026-08-25 | Code: S | equity_swap_involved: 0 | shares_owned_after: 309,906.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 50,000 shares of Employee Stock Option (Right to Buy) at $11.23 per share (Derivative)
  Date: 2026-08-25 | Code: M | Expires: 2030-06-16 | equity_swap_involved: 0 | shares_owned_after: 287,721.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.27 to $30.66 inclusive. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to the extent required by law.
• F2: Represents shares sold through a broker-assisted cashless exercise.
• F3: The options were exercisable as of July 1, 2025, when they were assumed by the issuer in connection with its acquisition of The AZEK Company Inc.